National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

BB-10901
An immunoconjugate of a humanized murine monoclonal antibody (huN-901) and DMI, a semi-synthetic derivative of the plant-derived ansa macrolide maytansine. The antibody moiety of BB-10901 selectively attaches to CD56 antigen, a neural cell adhesion molecule (NCAM)) expressed on the surface of cells of small cell lung cancer (SCLC) and other neuroendocrine (NE) tumors. Thus, the DMI conjugate is targeted specifically to CD56-expressing tumor cells, where it inhibits tubulin polymerization and assembly, resulting in inhibition of mitosis and cell cycle arrest in the S phase. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:huN901-DM1



Previous:barium sulfate, Barseb HC, basiliximab, BAY 56-3722, BayGam
Next:BCG vaccine, bcr-abl (b2a2)-derived peptide vaccine, bcr-abl (b3a2)-derived peptide vaccine, bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine, bcr-abl peptide vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov